Behavioral Neuroscience – Products

Newly-launched module set to accelerate drug discovery in therapeutic areas such as neuropsychiatry, epilepsy and neurodegeneration.

An analysis of NHS prescriptions data has revealed the huge potential for pharmacogenomics to reduce ineffective prescribing and adverse effects, which could save millions of pounds for the NHS.

Discover ioGABAergic Neurons from bit.bio and avoid unwanted excitatory neurons obscuring inhibitory signals in your experiments. Using a simple protocol, consistently go from cryopreserved cells to mature, functional, experiment-ready hiPSC-derived GABAergic neurons with >95% purity in 12 days.

In 2012, the Harvard Brain Tissue Resource Center lost 150 of its stored frozen brain samples, including one third of the world’s largest collection of autism brain tissue.

Blackrock Neurotech revealed its next-generation neural interface, Neuralace™, at Society for Neuroscience 2022.

The American scientist Ann Kennedy, PhD, assistant professor at Northwestern University, Chicago, USA has won the 2022 Eppendorf & Science Prize for Neurobiology for her work on the neural population dynamics that generate and maintain our emotions and behavioral drives.

Beckman Coulter Life Sciences announces that Suzanne Foster has been appointed as President of the company.

Beckman Coulter announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide.

The American scientist Amber L. Alhadeff, Ph.D., Principal Investigator at the Monell Chemical Senses Center and the University of Pennsylvania, USA has won the 2021 Eppendorf & Science Prize for Neurobiology for her work on the gut-brain control of hunger circuits.

Wesana Health announced its commitment to fund an initial US $1.5 million to assess the viability of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI).